ANCA相关肾小球肾炎20年人群队列的发病率、患病率、死亡率及慢性肾损伤
AAGN患者死亡率较普通人群显著升高(P<0.001),而无不伴肾小球肾炎的AAV患者死亡率与普通人群无差异。诊断时慢性化评分轻微至轻度预测1年肾功能恢复,临床诊断和ANCA特异性无预测作用。
要点
- AAGN年发病率2.0/10万,患病率35/10万(2015年1月1日)。
- AAGN死亡率较普通人群升高(P<0.001),无肾小球肾炎的AAV死亡率无差异。
- 诊断时慢性化评分轻微至轻度预测1年肾功能恢复。
核心结论
- 明尼苏达州AAGN年发病率为2.0/10万,患病率为35/10万。
- AAGN死亡率较无肾小球肾炎的AAV患者更差。
- 诊断时更严重的肾损伤预测更少的肾功能恢复。
研究设计与样本
- 发病率按2010年美国白人人口年龄和性别调整,患病率计算截至2015年1月1日。
- 生存率与明尼苏达州人群预期率比较,慢性肾损伤通过诊断时活检的慢性化评分评估。
- 结果在独立队列38例新诊断AAGN患者(1999-2014年)中重复验证。
主要发现
- AAGN年发病率为2.0/10万(95%CI 1.3-2.7),总体患病率为35/10万(95%CI 24-47)。
- AAGN死亡率升高(P<0.001),而无肾小球肾炎的AAV死亡率与普通人群无差异。
- 轻微至轻度慢性化评分预测1年肾功能恢复;临床诊断(肉芽肿性多血管炎 vs MPA)和ANCA特异性(蛋白酶3 vs MPO)无预测作用。
- 该观察在独立队列38例新诊断AAGN患者中重复验证。
临床怎么用
- 临床实践中应关注AAGN患者较高的死亡风险,尤其是与无肾小球肾炎的AAV患者相比。
- 诊断时肾活检慢性化评分可用于预测1年肾功能恢复可能性。
- 临床诊断和ANCA特异性不应作为预测肾功能恢复的依据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: True population-based clinical and outcomes data are lacking for anti-neutrophil cytoplasmic autoantibody (ANCA)-associated glomerulonephritis (AAGN). Therefore we aimed to estimate the incidence, prevalence and mortality of AAGN, as well as the relationship between the grade of chronic renal damage at presentation and renal and non-renal outcomes. METHODS: Patients with AAGN were identified among a population-based incident cohort of 57 Olmsted County residents diagnosed with ANCA-associated vasculitis (AAV) in 1996-2015. Incidence rates were age and sex adjusted to the 2010 US white population. Age- and sex-adjusted prevalence was calculated for 1 January 2015. Survival rates were compared with expected rates in the Minnesota population. Chronic renal damage was assessed by chronicity score (CS) on biopsies performed at diagnosis. RESULTS: Thirty-four (60%) patients had AAGN. Of these, 65% had microscopic polyangiitis (MPA) and 74% were myeloperoxidase (MPO)-ANCA positive. The annual incidence of AAGN was 2.0/100 000 population [95% confidence interval (CI) 1.3-2.7] and the overall prevalence was 35/100 000 (95% CI 24-47). Mortality for AAGN was increased (P < 0.001), whereas mortality for AAV without glomerulonephritis did not differ from the general population. Minimal to mild CS predicted recovery of renal function at 1 year; clinical diagnosis (granulomatosis with polyangiitis versus MPA) and ANCA specificity (proteinase 3 versus MPO) did not. This observation was replicated in an independent cohort of 38 newly diagnosed AAGN patients seen at our centre over the 1999-2014 period. CONCLUSIONS: The annual incidence and prevalence of AAGN in Minnesota are 2.0/100 000 and 35/100 000, respectively. Mortality is worse compared with AAV patients without glomerulonephritis. More advanced renal damage at diagnosis predicts less renal recovery.
引用
- Berti A, Cornec-Le Gall E, Cornec D, et al. Incidence, prevalence, mortality and chronic renal damage of anti-neutrophil cytoplasmic antibody-associated glomerulonephritis in a 20-year population-based cohort. Nephrol Dial Transplant. 2019. PMID: 30102330. doi:10.1093/ndt/gfy250
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。